CREB1

Across TCGA pan-cancer cohorts, CREB1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CREB1 data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CREB1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CREB1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where CREB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.697	0.383	<.001	47	view →
LUAD	DFS	Median	All	0.937	0.448	<.001	20	view →
UCEC	OS	Median	II,III,IV	0.647	1.000	.017	20	view →
HNSC	DFS	Quartile	III,IV	0.503	0.827	.016	19	view →
CCRCC	OS	Tertile	All	0.962	0.760	.025	12	view →
GBM	OS	Quartile	All	0.545	0.278	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CREB1–PDAC (OS)

Open the PDAC breakdown →